Description

Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Metabolism-sugar/lipid metabolism–C192H302N46O57—-[1]Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome. 26 June 2019.–2296814-85-0–4166.79–96.01–[Dapiglutide]–Metabolic Disease–DMSO : 50 mg/mL (ultrasonic)–GCGR—-GPCR/G Protein–Peptides